Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Using 68Ga-FAPI PET/CT to find thyroid cancer recurrence after surgery

Official title: The Value of 68Ga-FAPI PET/CT in Detecting Recurrent and Metastatic Lesions in Patients with Thyroid Cancer After Surgery

Run by Ruijin Hospital · NCT06800768 · Data updated 2026-11-12

This study is testing if a special type of scan can help find thyroid cancer that has come back after surgery in patients who are at risk for recurrence.

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment40 (estimated)
SponsorRuijin Hospital
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedFebruary 1, 2025
Main results expectedJanuary 31, 2030
Study endsJanuary 31, 2030
Registry record updatedJanuary 30, 2025
Trial IDNCT06800768 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-80 who have had surgery for thyroid cancer and are suspected of having recurrence or metastasis.

Probably not a fit

Patients with serious comorbidities or those who are pregnant or breastfeeding may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of 68Ga-FAPI PET/CT imaging in detecting recurrent and metastatic lesions in patients who have undergone surgery for thyroid cancer. Participants will be numbered and their medical history, including age and gender, will be recorded. When recurrence or metastasis is suspected, they will undergo a 68Ga-FAPI PET/CT scan, and the results will be compared to follow-up findings or histopathological results to assess accuracy.

Why it matters

Potential benefit: If successful, this study could improve the detection of recurrent thyroid cancer, leading to timely and potentially life-saving interventions.

How similar studies have gone: While the use of PET/CT imaging in cancer detection is established, the specific application of 68Ga-FAPI in thyroid cancer is relatively novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients with thyroid cancer who have undergone surgery and are suspected of recurrence or metastasis during clinical evaluation.
2. Signed and dated informed consent form.
3. Commitment to comply with research procedures and co-operation in the implementation of the full research process.
4. Aged 18-80 years old.

Exclusion Criteria:

1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
2. Intestinal perforation, complete intestinal obstruction.
3. Pregnant women and women who may be pregnant, women who are breastfeeding.
4. Non-compliant person.

Where it's running

  • Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.